Navigation Links
PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era
Date:9/23/2009

us to 20% of NDAs submitted from fiscal 2006 to 2008, down from 30% in 2005, suggesting that this designation is increasingly difficult to obtain.

"Despite the recent decrease in first-cycle approval rates and increase in overdue reviews for priority NDAs, we believe that there remains powerful evidence in our study to support what PAREXEL Consulting calls the "The Innovation Imperative"--the concept that the most innovative new drugs stand to receive greater regulatory attention and more rapid marketing approval," said Alberto Grignolo, Ph.D., Corporate Vice President, Global Strategy Services, PAREXEL Consulting. "Our analysis shows that pursuing priority review status and submitting quality NDAs that can be approved on the first review cycle should continue to be carefully considered by pharmaceutical companies when seeking FDA approval for new drugs and earlier launch dates."

Further supporting "The Innovation Imperative" are PAREXEL's findings in regard to New Molecular Entity (NME) approvals. The PAREXEL Consulting study shows that among the NMEs approved by FDA in the first five months of 2009, priority-rated NMEs were cleared 13.3 months faster than standard-rated NMEs.

The white paper "The Innovation Imperative in the Safety First Era" is part of PAREXEL Consulting's Intelligent Development Series, which provides data and insights in support of successful biopharmaceutical and medical device product development. The white paper is available at: www.ParexelConsulting.com/innovation-imperative.

* Center for Drug Evaluation and Research (CDER), a division of FDA

** Data as of April 1, 2009

About PAREXEL Consulting

PAREXEL Consulting, a division of PAREXEL International, provides integrated product d
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. PAREXEL International to Present at Robert Baird 2009 Healthcare Conference
3. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
4. PAREXEL International to Present at the Wachovia Equity Conference
5. PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting
6. PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention
7. PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
8. PAREXEL Receives BioSingapore Award for Best Performing CRO
9. PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
10. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
11. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... (PRWEB) April 17, 2015 Global ... the GTCbio Stem Cell Summit 2015 April 27 - ... the latest developments in all areas of stem cell ... of stem cells and regenerative medicine. , The ... trials, as well as translational research in stem cell ...
(Date:4/16/2015)... and OSAKA, Japan , ... Research Application (CiRA) of Kyoto University and Takeda ... will work together to develop clinical applications of ... heart failure, diabetes mellitus, neurological disorders and cancer ... Applications" (T-CiRA) is designed to expedite multiple research ...
(Date:4/16/2015)... CA (PRWEB) April 16, 2015 ... the Buzz of BIO Contest for the ... Organization (BIO), the 2015 BIO International Convention will take ... Philadelphia, Pennsylvania. During the Buzz of BIO contest, industry ... to see present at the conference. The community voting ...
(Date:4/16/2015)... CHARLOTTE, N.C. (PRWEB) April 16, 2015 ... North Carolina at Charlotte (UNC Charlotte) spin-out company, ... David L. Cooper, Ph.D., M.D., as Chief Operating ... 20 years of experience in developing clinical diagnostic ... oncology and infectious disease. , Cooper’s extensive career ...
Breaking Biology Technology:Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2
... May 13 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ... and products in the People,s Republic of China,announced that ... and Exchange Commission (SEC) that, if declared effective by ... to time, up to $100 million,of its common stock ...
... /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ) a ... in the People,s Republic of China,announced that it intends ... March 31, 2008, on Thursday, June 12, 2008., ... Thursday, June,12, 2008 at 9:00 a.m. Eastern Time to ...
... Patients Shipped in the Quarter ... ... BEDFORD, Mass., May 13 Insulet Corporation,(Nasdaq: PODD ), a ... today announced financial results for,the first quarter ended March 31, 2008., ...
Cached Biology Technology:Chindex International Announces Shelf Registration, Related Strategy and Guidance 2Chindex International Announces Shelf Registration, Related Strategy and Guidance 3Chindex International Announces Shelf Registration, Related Strategy and Guidance 4Chindex International Announces Shelf Registration, Related Strategy and Guidance 5Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 3Insulet Reports First Quarter 2008 Results 2Insulet Reports First Quarter 2008 Results 3Insulet Reports First Quarter 2008 Results 4Insulet Reports First Quarter 2008 Results 5Insulet Reports First Quarter 2008 Results 6Insulet Reports First Quarter 2008 Results 7
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... has already had dramatic effects on individual species, with ... migration. But, in a new study from the open-access ... Getz show that the impact of climate change on ... by a top predator - the reintroduced gray wolf ...
... A newly discovered mechanism by which an infectious fungus ... virulence, according to Howard Hughes Medical Institute investigators at ... in light following fungal invasion of the human body ... sparks infection, the researchers said. , The discovery in ...
... damage to the heart that can cause congestive ... limited ability of the myocardium to regenerate and ... now document the existence of a previously unrecognized ... therapeutic potency for myocardial tissue regeneration following myocardial ...
Cached Biology News:Gray wolves maintain the food chain in winter 2Light therapy may combat fungal infections, new evidence suggests 2Light therapy may combat fungal infections, new evidence suggests 3
Request Info...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: